CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
about
Transcriptome sequencing of tumor subpopulations reveals a spectrum of therapeutic options for squamous cell lung cancerSacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.Hidden among the crowd: differential DNA methylation-expression correlations in cancer occur at important oncogenic pathwaysFirst-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid TumorsMolecular targeted approaches for treatment of pancreatic cancer.Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).Identification of CEACAM5 as a Biomarker for Prewarning and Prognosis in Gastric Cancer.Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.Using antibodies to target cancer therapeutics.Designing immunoconjugates for cancer therapy.Challenges in SN38 drug delivery: current success and future directions.Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.Prospects and progress of antibody-drug conjugates in solid tumor therapies.Evolving Strategies for Target Selection for Antibody-Drug Conjugates.Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.Carcinoembryonic antigen interacts with TGF-{beta} receptor and inhibits TGF-{beta} signaling in colorectal cancers.Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study.HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutami
P2860
Q28488566-3AB046E3-B9F6-49FF-B148-2BB12CF4AB9FQ30101057-272887CB-DEFB-4B3C-92F6-28D0863D9519Q35600057-44D99F91-1B34-4514-8984-394189DD818FQ36021635-4318F731-73AF-4B6F-93C0-D9D885790735Q36174910-14046264-F11B-4B4D-8876-523CAF91B41BQ36356001-C2F6D2CB-62FD-4841-B8C9-87F2BA404709Q36774495-D3EAE718-0FA1-47C1-805A-85E689C5C4A2Q37731433-1662973F-C74B-498C-AC8E-A271D29D6BEAQ38014920-0C417436-70E5-4479-B446-3B661AB8FEB9Q38017203-C269882F-6E45-4ED9-BB72-367F3C30114FQ38553224-3FF7DF11-892D-417A-841E-BF73AF27039DQ38798481-D53FCAD7-C944-40C3-B95D-DBE23DF58F98Q38798525-C86930AC-1B50-456F-8A9E-237AC3D6AB52Q38920359-EDD91D5E-88A5-4889-993B-C850C00B09DEQ39564060-699AA523-A060-4F2B-9ED4-125D78AEBC72Q39648681-16595FF1-A147-4551-889B-D12A3A55441BQ41282870-F77AAE4D-B5A0-459E-B486-047E47F7C048Q47143718-4ABAA521-84A8-45EB-B3D8-AA251B1273C5Q47658039-DB43855B-79EE-4339-A490-FB5347120EADQ55004240-F580F2E0-5B3F-4F7E-BD58-83B810F1CE01
P2860
CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CEACAM5-targeted therapy of hu ...... uzumab-SN-38 immunoconjugates.
@en
CEACAM5-targeted therapy of hu ...... uzumab-SN-38 immunoconjugates.
@nl
type
label
CEACAM5-targeted therapy of hu ...... uzumab-SN-38 immunoconjugates.
@en
CEACAM5-targeted therapy of hu ...... uzumab-SN-38 immunoconjugates.
@nl
prefLabel
CEACAM5-targeted therapy of hu ...... uzumab-SN-38 immunoconjugates.
@en
CEACAM5-targeted therapy of hu ...... uzumab-SN-38 immunoconjugates.
@nl
P2093
P2860
P1476
CEACAM5-targeted therapy of hu ...... uzumab-SN-38 immunoconjugates.
@en
P2093
David M Goldenberg
Hans J Hansen
Serengulam V Govindan
Sung-Ju Moon
Thomas M Cardillo
P2860
P304
P356
10.1158/1078-0432.CCR-09-0586
P407
P577
2009-09-29T00:00:00Z